This report was recently updated on July 20 2024 with the latest and most recent
market numbers
Global RSV Vaccine Market Size, Trends & Analysis - Forecasts to 2029 By Vaccine Type (Viral Vaccine and Bacterial Vaccine), By Age Group (Pediatric and Adult), By Route of Administration (Intramuscular and Intranasal), and By Region (North America, Asia Pacific, Central and South America, Europe, and Middle East and Africa), Competitive Landscape, Company Market Share Analysis, and End User Analysis
The global respiratory syncytial virus (RSV) vaccine market is estimated to exhibit a CAGR of 4.9% from 2024 to 2029.
The primary factors propelling the market growth are the rising incorporation of respiratory syncytial virus vaccines into childhood vaccination schedules and increasing cases of respiratory syncytial virus. As RSV cases surge, there is a burgeoning urgency to address this viral menace through innovative solutions. RSV vaccination strategies are becoming pivotal, with a sharp focus on RSV vaccine development aimed at curbing transmission and mitigating disease burden. The RSV vaccine efficacy is under intense scrutiny, fostering research endeavors to enhance their effectiveness and broaden their applicability across diverse demographics. Moreover, the growing global RSV vaccine demand also highlights the urgent need for easily available and reasonably priced preventative strategies to protect vulnerable groups, especially the elderly and newborns, from the morbidity and death associated with RSV. For instance, the U.S. Centers for Disease Control and Prevention (2023) estimates that RSV causes 6,000–10,000 fatalities and 60,000–120,000 hospital admissions annually in the United States among persons 65 years of age and older.
Implementation of nationwide and global RSV immunization programs coupled with the heightened emphasis on RSV prevention measures are expected to support market growth. With a concerted focus on preventive healthcare, governments, and healthcare organizations are increasingly advocating for the inclusion of RSV vaccination in routine immunization schedules. Maternal immunization for RSV is emerging as a promising strategy to confer passive immunity to newborns, amplifying the protective shield against early RSV infections. Moreover, the toolkit against this viral danger is being expanded by the development of many RSV vaccine candidates, bolstering confidence in RSV vaccine safety and efficacy profiles. As regulatory bodies and public health authorities continue to endorse RSV vaccine recommendations, the market is witnessing a surge in demand for these preventive interventions.
Increasing RSV vaccination coverage rates and rising investment in RSV vaccine clinical trials propel market growth. With growing recognition of the significant burden posed by respiratory syncytial virus (RSV), pharmaceutical companies and biotech firms are channeling substantial resources into RSV vaccine research and development. This heightened focus is fostering collaboration between RSV vaccine manufacturers and research institutions, accelerating the advancement of novel vaccine candidates. As clinical trials progress, anticipating successful outcomes drives optimism surrounding the future availability of effective RSV vaccines. Furthermore, this investment is increasing focus on RSV vaccine distribution strategies, particularly in regions with pediatric infectious disease vaccine shortage.
Emerging RSV vaccine technologies, including novel approaches such as mRNA vaccines and nanoparticle-based formulations, are creating opportunities in the market by providing enhanced efficacy and safety. Additionally, an RSV vaccine market analysis shows a favorable regulatory environment and government measures that encourage vaccine development and adoption while also providing opportunities.
However, fluctuating RSV vaccine pricing trends and lack of awareness among healthcare professionals and the general public about RSV may impede market growth.
The viral vaccine segment is expected to hold the largest share of the market over the forecast period. Viral vaccines for RSV frequently use inactivated or weakened virus strains, which frequently cause a strong immunological reaction in the recipient's body. Patients and healthcare professionals favor viral vaccinations due to their effectiveness in inducing immune responses against RSV.
The bacterial vaccine segment is expected to be the fastest-growing segment in the market from 2024 to 2029. Vaccines using bacterial vectors can provide cross-protection against many RSV strains or subtypes. Given that RSV has antigenic diversity, this broad-spectrum protection is highly preferred in the fight against the virus. The market appeal of bacterial vaccines is increased by their capacity to target several strains of RSV.
The pediatric segment is expected to hold the largest share of the market over the forecast period. Severe RSV infections are particularly common in infants and young children and can cause consequences, including pneumonia and bronchiolitis. RSV is a significant cause of respiratory illness in children under five years old, with infants under six months being at the highest risk. As a result, there is a strong demand for effective vaccines to protect this vulnerable population.
The adult segment is anticipated to be the fastest-growing segment in the market from 2024 to 2029. RSV is frequently linked to pediatric populations, but it also poses a severe risk to adult health, especially in older persons and those with underlying medical issues. More emphasis is being placed on the requirement of immunization to avoid severe respiratory infections as awareness of RSV-related morbidity and death in adults grows.
The intramuscular segment is expected to hold the largest share of the market over the forecast period. Intramuscular administration is a well-established and widely used route for vaccine delivery. It is well-known to both patients and healthcare professionals, and it offers a consistent and easy way to administer the vaccination and absorb it into circulation. Intramuscular injections have a dominant position in the RSV vaccination industry due to their familiarity and dependability.
The intranasal segment is anticipated to be the fastest-growing segment in the market from 2024 to 2029. Compared to systemic delivery techniques like intramuscular injection, intranasal vaccines have the potential to elicit larger and stronger immunological reactions. Intranasal vaccination can stimulate both systemic and mucosal immune systems for complete protection. The mucosal immune system is essential for defense against respiratory viruses such as RSV.
North America is expected to be the largest region in the global market. Governments and public health agencies in North America prioritize the prevention of infectious diseases like RSV, particularly in vulnerable populations such as infants, older adults, and individuals with underlying health conditions. Vaccination programs are integral to public health initiatives aimed at reducing the impact of RSV on morbidity, mortality, and healthcare resources.
Asia Pacific is anticipated to witness rapid growth during the forecast period. In the Asia Pacific region, maternity and child health programs prioritize measures that enhance maternal and child health outcomes, such as vaccination against illnesses that can be prevented. To shield infants and children against serious RSV infections during their delicate early months of life, maternal immunization against the virus is becoming increasingly popular.
GlaxoSmithKline plc (GSK), Novavax, Inc., AstraZeneca plc, Pfizer Inc., Sanofi Pasteur, Johnson & Johnson - Merck & Co., Inc., Bavarian Nordic, Bharat Biotec, and Serum Institute of India, among others, are some of the key players in the global RSV vaccine market.
Please note: This is not an exhaustive list of companies profiled in the report.
In May 2023, the GSK RSV vaccine received the U.S. Food and Drug Administration (FDA) approval to protect people 60 years of age and older against respiratory syncytial virus (RSV)-induced lower respiratory tract disease (LRTD).
In August 2023, the ABRYSVO vaccine, developed by Pfizer, was approved by the U.S. FDA to prevent respiratory syncytial virus (RSV) in infants by actively immunizing pregnant women between 32 and 36 weeks of gestational age.
1 STRATEGIC INSIGHTS ON NEW REVENUE POCKETS
1.1 Strategic Opportunity & Attractiveness Analysis
1.1.1 Hot Revenue Pockets
1.1.2 Market Attractiveness Score
1.1.3 Revenue Impacting Opportunity
1.1.4 High Growing Region/Country
1.1.5 Competitor Analysis
1.1.6 Consumer Analysis
1.2 Global Market Estimates' View
1.3 Strategic Insights across Business Functions
1.3.1 For Chief Executive Officers
1.3.2 For Chief Marketing Officers
1.3.3 For Chief Strategy Officers
1.4 Evaluate the Potential of your Existing Business Lines vs. New Lines to Enter Into
2 TECHNOLOGICAL TRENDS
2.1 Technological Adoption Rate
2.2 Current Trend Impact Analysis
2.3 Future Trend Impact Analysis
3 GLOBAL RSV VACCINE MARKET OUTLOOK
3.1 Market Pyramid Analysis
3.1.1 Introduction
3.1.2 Adjacent Market Opportunities
3.1.3 Ancillary Market Opportunities
3.2 Demand Side Analysis
3.2.1 Market Drivers: Impact Analysis
3.2.2 Market Restraints: Impact Analysis
3.2.3 Market Opportunities: Impact Analysis
3.2.4 Market Challenges: Impact Analysis
3.3 Supply Side Analysis
3.3.1 Porter’s Five Forces Analysis
3.3.1.1 Threat of New Entrants
3.3.1.2 Threat of New Substitutes
3.3.1.3 Bargaining Power of Suppliers
3.3.1.4 Bargaining Power of Buyers
3.3.1.5 Intensity of Competitive Rivalry
3.3.2 SWOT Analysis; By Factor (Political & Legal, Economic, and Technological)
3.3.2.1 Political Landscape
3.3.2.2 Economic Landscape
3.3.2.3 Social Landscape
3.3.2.4 Technology Landscape
3.3.3 Value Chain Analysis
3.3.4 Trend Analysis
3.3.5 Gap Analysis
3.3.6 Cost Analysis
4 GLOBAL RSV VACCINE MARKET, BY VACCINE TYPE
4.1 Introduction
4.2 RSV Vaccine Market: Vaccine Type Scope Key Takeaways
4.3 Revenue Growth Analysis, 2023 & 2029
4.4 Viral Vaccine
4.4.1 Viral Vaccine Market Estimates and Forecast, 2021-2029 (USD Million)
4.5 Bacterial Vaccine
4.5.1 Bacterial Vaccine Market Estimates and Forecast, 2021-2029 (USD Million)
5 GLOBAL RSV VACCINE MARKET, BY AGE GROUP
5.1 Introduction
5.2 RSV Vaccine Market: Age Group Scope Key Takeaways
5.3 Revenue Growth Analysis, 2023 & 2029
5.4 Pediatric
5.4.1 Pediatric Market Estimates and Forecast, 2021-2029 (USD Million)
5.5 Adult
5.5.1 Adult Market Estimates and Forecast, 2021-2029 (USD Million)
6 GLOBAL RSV VACCINE MARKET, BY ROUTE OF ADMINISTRATION
6.1 Introduction
6.2 RSV Vaccine Market: Route of Administration Scope Key Takeaways
6.3 Revenue Growth Analysis, 2023 & 2029
6.4 Intramuscular
6.4.1 Intramuscular Market Estimates and Forecast, 2021-2029 (USD Million)
6.5 Intranasal
6.5.1 Intranasal Market Estimates and Forecast, 2021-2029 (USD Million)
7 GLOBAL RSV VACCINE MARKET, BY REGION
7.1 Introduction
7.2 North America RSV Vaccine Market Estimates and Forecast, 2021-2029 (USD Million)
7.2.1 By Vaccine Type
7.2.2 By Age Group
7.2.3 By Route of Administration
7.2.4 By Country
7.2.4.1 U.S. RSV Vaccine Market Estimates and Forecast, 2021-2029 (USD Million)
7.2.4.1.1 By Vaccine Type
7.2.4.1.2 By Age Group
7.2.4.1.3 By Route of Administration
7.2.4.2 Canada RSV Vaccine Market Estimates and Forecast, 2021-2029 (USD Million)
7.2.4.2.1 By Vaccine Type
7.2.4.2.2 By Age Group
7.2.4.2.3 By Route of Administration
7.2.4.3 Mexico RSV Vaccine Market Estimates and Forecast, 2021-2029 (USD Million)
7.2.4.3.1 By Vaccine Type
7.2.4.3.2 By Age Group
7.2.4.3.3 By Route of Administration
7.3 Europe RSV Vaccine Market Estimates and Forecast, 2021-2029 (USD Million)
7.3.1 By Vaccine Type
7.3.2 By Age Group
7.3.3 By Route of Administration
7.3.4 By Country
7.3.4.1 Germany RSV Vaccine Market Estimates and Forecast, 2021-2029 (USD Million)
7.3.4.1.1 By Vaccine Type
7.3.4.1.2 By Age Group
7.3.4.1.3 By Route of Administration
7.3.4.2 U.K. RSV Vaccine Market Estimates and Forecast, 2021-2029 (USD Million)
7.3.4.2.1 By Vaccine Type
7.3.4.2.2 By Age Group
7.3.4.2.3 By Route of Administration
7.3.4.3 France RSV Vaccine Market Estimates and Forecast, 2021-2029 (USD Million)
7.3.4.3.1 By Vaccine Type
7.3.4.3.2 By Age Group
7.3.4.3.3 By Route of Administration
7.3.4.4 Italy RSV Vaccine Market Estimates and Forecast, 2021-2029 (USD Million)
7.3.4.4.1 By Vaccine Type
7.3.4.4.2 By Age Group
7.2.4.4.3 By Route of Administration
7.3.4.5 Spain RSV Vaccine Market Estimates and Forecast, 2021-2029 (USD Million)
7.3.4.5.1 By Vaccine Type
7.3.4.5.2 By Age Group
7.2.4.5.3 By Route of Administration
7.3.4.6 Netherlands RSV Vaccine Market Estimates and Forecast, 2021-2029 (USD Million)
7.3.4.6.1 By Vaccine Type
7.3.4.6.2 By Age Group
7.2.4.6.3 By Route of Administration
7.3.4.7 Rest of Europe RSV Vaccine Market Estimates and Forecast, 2021-2029 (USD Million)
7.3.4.7.1 By Vaccine Type
7.3.4.7.2 By Age Group
7.2.4.7.3 By Route of Administration
7.4 Asia Pacific RSV Vaccine Market Estimates and Forecast, 2021-2029 (USD Million)
7.4.1 By Vaccine Type
7.4.2 By Age Group
7.4.3 By Route of Administration
7.4.4 By Country
7.4.4.1 China RSV Vaccine Market Estimates and Forecast, 2021-2029 (USD Million)
7.4.4.1.1 By Vaccine Type
7.4.4.1.2 By Age Group
7.4.4.1.3 By Route of Administration
7.4.4.2 Japan RSV Vaccine Market Estimates and Forecast, 2021-2029 (USD Million)
7.4.4.2.1 By Vaccine Type
7.4.4.2.2 By Age Group
7.4.4.2.3 By Route of Administration
7.4.4.3 India RSV Vaccine Market Estimates and Forecast, 2021-2029 (USD Million)
7.4.4.3.1 By Vaccine Type
7.4.4.3.2 By Age Group
7.4.4.3.3 By Route of Administration
7.4.4.4 South Korea RSV Vaccine Market Estimates and Forecast, 2021-2029 (USD Million)
7.4.4.4.1 By Vaccine Type
7.4.4.4.2 By Age Group
7.4.4.4.3 By Route of Administration
7.4.4.5 Singapore RSV Vaccine Market Estimates and Forecast, 2021-2029 (USD Million)
7.4.4.5.1 By Vaccine Type
7.4.4.5.2 By Age Group
7.4.4.5.3 By Route of Administration
7.4.4.6 Malaysia RSV Vaccine Market Estimates and Forecast, 2021-2029 (USD Million)
7.4.4.6.1 By Vaccine Type
7.4.4.6.2 By Age Group
7.4.4.6.3 By Route of Administration
7.4.4.7 Thailand RSV Vaccine Market Estimates and Forecast, 2021-2029 (USD Million)
7.4.4.7.1 By Vaccine Type
7.4.4.7.2 By Age Group
7.4.4.7.3 By Route of Administration
7.4.4.8 Indonesia RSV Vaccine Market Estimates and Forecast, 2021-2029 (USD Million)
7.4.4.8.1 By Vaccine Type
7.4.4.8.2 By Age Group
7.4.4.8.3 By Route of Administration
7.4.4.9 Vietnam RSV Vaccine Market Estimates and Forecast, 2021-2029 (USD Million)
7.4.4.9.1 By Vaccine Type
7.4.4.9.2 By Age Group
7.4.4.9.3 By Route of Administration
7.4.4.10 Taiwan RSV Vaccine Market Estimates and Forecast, 2021-2029 (USD Million)
7.4.4.10.1 By Vaccine Type
7.4.4.10.2 By Age Group
7.4.4.10.3 By Route of Administration
7.4.4.11 Rest of Asia Pacific RSV Vaccine Market Estimates and Forecast, 2021-2029 (USD Million)
7.4.4.11.1 By Vaccine Type
7.4.4.11.2 By Age Group
7.4.4.11.3 By Route of Administration
7.5 Middle East and Africa RSV Vaccine Market Estimates and Forecast, 2021-2029 (USD Million)
7.5.1 By Vaccine Type
7.5.2 By Age Group
7.5.3 By Route of Administration
7.5.4 By Country
7.5.4.1 Saudi Arabia RSV Vaccine Market Estimates and Forecast, 2021-2029 (USD Million)
7.5.4.1.1 By Vaccine Type
7.5.4.1.2 By Age Group
7.5.4.1.3 By Route of Administration
7.5.4.2 U.A.E. RSV Vaccine Market Estimates and Forecast, 2021-2029 (USD Million)
7.5.4.2.1 By Vaccine Type
7.5.4.2.2 By Age Group
7.5.4.2.3 By Route of Administration
7.5.4.3 Israel RSV Vaccine Market Estimates and Forecast, 2021-2029 (USD Million)
7.5.4.3.1 By Vaccine Type
7.5.4.3.2 By Age Group
7.5.4.3.3 By Route of Administration
7.5.4.4 South Africa RSV Vaccine Market Estimates and Forecast, 2021-2029 (USD Million)
7.5.4.4.1 By Vaccine Type
7.5.4.4.2 By Age Group
7.5.4.4.3 By Route of Administration
7.5.4.5 Rest of Middle East and Africa RSV Vaccine Market Estimates and Forecast, 2021-2029 (USD Million)
7.5.4.5.1 By Vaccine Type
7.5.4.5.2 By Age Group
7.5.4.5.2 By Route of Administration
7.6 Central and South America RSV Vaccine Market Estimates and Forecast, 2021-2029 (USD Million)
7.6.1 By Vaccine Type
7.6.2 By Age Group
7.6.3 By Route of Administration
7.6.4 By Country
7.6.4.1 Brazil RSV Vaccine Market Estimates and Forecast, 2021-2029 (USD Million)
7.6.4.1.1 By Vaccine Type
7.6.4.1.2 By Age Group
7.6.4.1.3 By Route of Administration
7.6.4.2 Argentina RSV Vaccine Market Estimates and Forecast, 2021-2029 (USD Million)
7.6.4.2.1 By Vaccine Type
7.6.4.2.2 By Age Group
7.6.4.2.3 By Route of Administration
7.6.4.3 Chile RSV Vaccine Market Estimates and Forecast, 2021-2029 (USD Million)
7.6.4.3.1 By Vaccine Type
7.6.4.3.2 By Age Group
7.6.4.3.3 By Route of Administration
7.6.4.4 Rest of Central and South America RSV Vaccine Market Estimates and Forecast, 2021-2029 (USD Million)
7.6.4.4.1 By Vaccine Type
7.6.4.4.2 By Age Group
7.6.4.4.3 By Route of Administration
8 COMPETITIVE LANDCAPE
8.1 Company Market Share Analysis
8.2 Four Quadrant Positioning Matrix
8.2.1 Market Leaders
8.2.2 Market Visionaries
8.2.3 Market Challengers
8.2.4 Niche Market Players
8.3 Vendor Landscape
8.3.1 North America
8.3.2 Europe
8.3.3 Asia Pacific
8.3.4 Rest of the World
8.4 Company Profiles
8.4.1 GlaxoSmithKline plc (GSK)
8.4.1.1 Business Description & Financial Analysis
8.4.1.2 SWOT Analysis
8.4.1.3 Products & Services Offered
8.4.1.4 Strategic Alliances between Business Partners
8.4.2 Novavax, Inc.
8.4.2.1 Business Description & Financial Analysis
8.4.2.2 SWOT Analysis
8.4.2.3 Products & Services Offered
8.4.2.4 Strategic Alliances between Business Partners
8.4.3 AstraZeneca plc
8.4.3.1 Business Description & Financial Analysis
8.4.3.2 SWOT Analysis
8.4.3.3 Products & Services Offered
8.4.3.4 Strategic Alliances between Business Partners
8.4.4 Pfizer Inc.
8.4.4.1 Business Description & Financial Analysis
8.4.4.2 SWOT Analysis
8.4.4.3 Products & Services Offered
8.4.4.4 Strategic Alliances between Business Partners
8.4.5 Sanofi Pasteur
8.4.5.1 Business Description & Financial Analysis
8.4.5.2 SWOT Analysis
8.4.5.3 Products & Services Offered
8.4.5.4 Strategic Alliances between Business Partners
8.4.6 JOHNSON & JOHNSON - MERCK & CO., INC.
8.4.6.1 Business Description & Financial Analysis
8.4.6.2 SWOT Analysis
8.4.6.3 Products & Services Offered
8.4.6.4 Strategic Alliances between Business Partners
8.4.7 Bavarian Nordic
8.4.7.1 Business Description & Financial Analysis
8.4.7.2 SWOT Analysis
8.4.7.3 Products & Services Offered
8.4.8.4 Strategic Alliances between Business Partners
8.4.8 Bharat Biotec
8.4.8.1 Business Description & Financial Analysis
8.4.8.2 SWOT Analysis
8.4.8.3 Products & Services Offered
8.4.8.4 Strategic Alliances between Business Partners
8.4.9 Serum Institute of India
8.4.9.1 Business Description & Financial Analysis
8.4.9.2 SWOT Analysis
8.4.9.3 Products & Services Offered
8.4.9.4 Strategic Alliances between Business Partners
8.4.10 Other Companies
8.4.10.1 Business Description & Financial Analysis
8.4.10.2 SWOT Analysis
8.4.10.3 Products & Services Offered
8.4.10.4 Strategic Alliances between Business Partners
9 RESEARCH METHODOLOGY
9.1 Market Introduction
9.1.1 Market Definition
9.1.2 Market Scope & Segmentation
9.2 Information Procurement
9.2.1 Secondary Research
9.2.1.1 Purchased Databases
9.2.1.2 GMEs Internal Data Repository
9.2.1.3 Secondary Resources & Third Party Perspectives
9.2.1.4 Company Information Sources
9.2.2 Primary Research
9.2.2.1 Various Types of Respondents for Primary Interviews
9.2.2.2 Number of Interviews Conducted throughout the Research Process
9.2.2.3 Primary Stakeholders
9.2.2.4 Discussion Guide for Primary Participants
9.2.3 Expert Panels
9.2.3.1 Expert Panels Across 30+ Industry
9.2.4 Paid Local Experts
9.2.4.1 Paid Local Experts Across 30+ Industry Across each Region
9.3 Market Estimation
9.3.1 Top-Down Approach
9.3.1.1 Macro-Economic Indicators Considered
9.3.1.2 Micro-Economic Indicators Considered
9.3.2 Bottom Up Approach
9.3.2.1 Company Share Analysis Approach
9.3.2.2 Estimation of Potential Type Sales
9.4 Data Triangulation
9.4.1 Data Collection
9.4.2 Time Series, Cross Sectional & Panel Data Analysis
9.4.3 Cluster Analysis
9.5 Analysis and Output
9.5.1 Inhouse AI Based Real Time Analytics Tool
9.5.2 Output From Desk & Primary Research
9.6 Research Assumptions & Limitations
9.7.1 Research Assumptions
9.7.2 Research Limitations
LIST OF TABLES
1 Global RSV Vaccine Market, By Vaccine Type, 2021-2029 (USD Mllion)
2 Viral Vaccine Market, By Region, 2021-2029 (USD Mllion)
3 Bacterial Vaccine Market, By Region, 2021-2029 (USD Mllion)
4 Global RSV Vaccine Market, By Age Group, 2021-2029 (USD Mllion)
5 Pediatric Market, By Region, 2021-2029 (USD Mllion)
6 Adult Market, By Region, 2021-2029 (USD Mllion)
7 Global RSV Vaccine Market, By Route of Administration, 2021-2029 (USD Mllion)
8 Intramuscular Market, By Region, 2021-2029 (USD Mllion)
9 Intranasal Market, By Region, 2021-2029 (USD Mllion)
10 Regional Analysis, 2021-2029 (USD Mllion)
11 North America RSV Vaccine Market, By Vaccine Type, 2021-2029 (USD Million)
12 North America RSV Vaccine Market, By Age Group, 2021-2029 (USD Million)
13 North America RSV Vaccine Market, By Route of Administration, 2021-2029 (USD Million)
14 North America RSV Vaccine Market, By Country, 2021-2029 (USD Million)
15 U.S. RSV Vaccine Market, By Vaccine Type, 2021-2029 (USD Million)
16 U.S. RSV Vaccine Market, By Age Group, 2021-2029 (USD Million)
17 U.S. RSV Vaccine Market, By Route of Administration, 2021-2029 (USD Million)
18 Canada RSV Vaccine Market, By Vaccine Type, 2021-2029 (USD Million)
19 Canada RSV Vaccine Market, By Age Group, 2021-2029 (USD Million)
20 Canada RSV Vaccine Market, By Route of Administration, 2021-2029 (USD Million)
21 Mexico RSV Vaccine Market, By Vaccine Type, 2021-2029 (USD Million)
22 Mexico RSV Vaccine Market, By Age Group, 2021-2029 (USD Million)
23 Mexico RSV Vaccine Market, By Route of Administration, 2021-2029 (USD Million)
24 Europe RSV Vaccine Market, By Vaccine Type, 2021-2029 (USD Million)
25 Europe RSV Vaccine Market, By Age Group, 2021-2029 (USD Million)
26 Europe RSV Vaccine Market, By Route of Administration, 2021-2029 (USD Million)
27 Europe RSV Vaccine Market, By Country 2021-2029 (USD Million)
28 Germany RSV Vaccine Market, By Vaccine Type, 2021-2029 (USD Million)
29 Germany RSV Vaccine Market, By Age Group, 2021-2029 (USD Million)
30 Germany RSV Vaccine Market, By Route of Administration, 2021-2029 (USD Million)
31 U.K. RSV Vaccine Market, By Vaccine Type, 2021-2029 (USD Million)
32 U.K. RSV Vaccine Market, By Age Group, 2021-2029 (USD Million)
33 U.K. RSV Vaccine Market, By Route of Administration, 2021-2029 (USD Million)
34 France RSV Vaccine Market, By Vaccine Type, 2021-2029 (USD Million)
35 France RSV Vaccine Market, By Age Group, 2021-2029 (USD Million)
36 France RSV Vaccine Market, By Route of Administration, 2021-2029 (USD Million)
37 Italy RSV Vaccine Market, By Vaccine Type, 2021-2029 (USD Million)
38 Italy RSV Vaccine Market, By Age Group, 2021-2029 (USD Million)
39 Italy RSV Vaccine Market, By Route of Administration, 2021-2029 (USD Million)
40 Spain RSV Vaccine Market, By Vaccine Type, 2021-2029 (USD Million)
41 Spain RSV Vaccine Market, By Age Group, 2021-2029 (USD Million)
42 Spain RSV Vaccine Market, By Route of Administration, 2021-2029 (USD Million)
43 Netherlands RSV Vaccine Market, By Vaccine Type, 2021-2029 (USD Million)
44 Netherlands RSV Vaccine Market, By Age Group, 2021-2029 (USD Million)
45 Netherlands RSV Vaccine Market, By Route of Administration, 2021-2029 (USD Million)
46 Rest Of Europe RSV Vaccine Market, By Vaccine Type, 2021-2029 (USD Million)
47 Rest Of Europe RSV Vaccine Market, By Age Group, 2021-2029 (USD Million)
48 Rest of Europe RSV Vaccine Market, By Route of Administration, 2021-2029 (USD Million)
49 Asia Pacific RSV Vaccine Market, By Vaccine Type, 2021-2029 (USD Million)
50 Asia Pacific RSV Vaccine Market, By Age Group, 2021-2029 (USD Million)
51 Asia Pacific RSV Vaccine Market, By Route of Administration, 2021-2029 (USD Million)
52 Asia Pacific RSV Vaccine Market, By Country, 2021-2029 (USD Million)
53 China RSV Vaccine Market, By Vaccine Type, 2021-2029 (USD Million)
54 China RSV Vaccine Market, By Age Group, 2021-2029 (USD Million)
55 China RSV Vaccine Market, By Route of Administration, 2021-2029 (USD Million)
56 India RSV Vaccine Market, By Vaccine Type, 2021-2029 (USD Million)
57 India RSV Vaccine Market, By Age Group, 2021-2029 (USD Million)
58 India RSV Vaccine Market, By Route of Administration, 2021-2029 (USD Million)
59 Japan RSV Vaccine Market, By Vaccine Type, 2021-2029 (USD Million)
60 Japan RSV Vaccine Market, By Age Group, 2021-2029 (USD Million)
61 Japan RSV Vaccine Market, By Route of Administration, 2021-2029 (USD Million)
62 South Korea RSV Vaccine Market, By Vaccine Type, 2021-2029 (USD Million)
63 South Korea RSV Vaccine Market, By Age Group, 2021-2029 (USD Million)
64 South Korea RSV Vaccine Market, By Route of Administration, 2021-2029 (USD Million)
65 malaysia RSV Vaccine Market, By Vaccine Type, 2021-2029 (USD Million)
66 malaysia RSV Vaccine Market, By Age Group, 2021-2029 (USD Million)
67 malaysia RSV Vaccine Market, By Route of Administration, 2021-2029 (USD Million)
68 Thailand RSV Vaccine Market, By Vaccine Type, 2021-2029 (USD Million)
69 Thailand RSV Vaccine Market, By Age Group, 2021-2029 (USD Million)
70 Thailand RSV Vaccine Market, By Route of Administration, 2021-2029 (USD Million)
71 Indonesia RSV Vaccine Market, By Vaccine Type, 2021-2029 (USD Million)
72 Indonesia RSV Vaccine Market, By Age Group, 2021-2029 (USD Million)
73 Indonesia RSV Vaccine Market, By Route of Administration, 2021-2029 (USD Million)
74 Vietnam RSV Vaccine Market, By Vaccine Type, 2021-2029 (USD Million)
75 Vietnam RSV Vaccine Market, By Age Group, 2021-2029 (USD Million)
76 Vietnam RSV Vaccine Market, By Route of Administration, 2021-2029 (USD Million)
77 Taiwan RSV Vaccine Market, By Vaccine Type, 2021-2029 (USD Million)
78 Taiwan RSV Vaccine Market, By Age Group, 2021-2029 (USD Million)
79 Taiwan RSV Vaccine Market, By Route of Administration, 2021-2029 (USD Million)
80 Rest of Asia Pacific RSV Vaccine Market, By Vaccine Type, 2021-2029 (USD Million)
81 Rest of Asia Pacific RSV Vaccine Market, By Age Group, 2021-2029 (USD Million)
82 Rest of Asia Pacific RSV Vaccine Market, By Route of Administration, 2021-2029 (USD Million)
83 Middle East and Africa RSV Vaccine Market, By Vaccine Type, 2021-2029 (USD Million)
84 Middle East and Africa RSV Vaccine Market, By Age Group, 2021-2029 (USD Million)
85 Middle East and Africa RSV Vaccine Market, By Route of Administration, 2021-2029 (USD Million)
86 Middle East and Africa RSV Vaccine Market, By Country, 2021-2029 (USD Million)
87 Saudi Arabia RSV Vaccine Market, By Vaccine Type, 2021-2029 (USD Million)
88 Saudi Arabia RSV Vaccine Market, By Age Group, 2021-2029 (USD Million)
89 Saudi Arabia RSV Vaccine Market, By Route of Administration, 2021-2029 (USD Million)
90 UAE RSV Vaccine Market, By Vaccine Type, 2021-2029 (USD Million)
91 UAE RSV Vaccine Market, By Age Group, 2021-2029 (USD Million)
92 UAE RSV Vaccine Market, By Route of Administration, 2021-2029 (USD Million)
93 Israel RSV Vaccine Market, By Vaccine Type, 2021-2029 (USD Million)
94 Israel RSV Vaccine Market, By Age Group, 2021-2029 (USD Million)
95 Israel RSV Vaccine Market, By Route of Administration, 2021-2029 (USD Million)
96 South Africa RSV Vaccine Market, By Vaccine Type, 2021-2029 (USD Million)
97 South Africa RSV Vaccine Market, By Age Group, 2021-2029 (USD Million)
98 South Africa RSV Vaccine Market, By Route of Administration, 2021-2029 (USD Million)
99 Rest of Middle East and Africa RSV Vaccine Market, By Vaccine Type, 2021-2029 (USD Million)
100 Rest of Middle East and Africa RSV Vaccine Market, By Age Group, 2021-2029 (USD Million)
101 Rest of Middle East and Africa RSV Vaccine Market, By Route of Administration, 2021-2029 (USD Million)
102 Central and South America RSV Vaccine Market, By Vaccine Type, 2021-2029 (USD Million)
103 Central and South America RSV Vaccine Market, By Age Group, 2021-2029 (USD Million)
104 Central and South America RSV Vaccine Market, By Route of Administration, 2021-2029 (USD Million)
105 Central and South America RSV Vaccine Market, By Country, 2021-2029 (USD Million)
106 Brazil RSV Vaccine Market, By Vaccine Type, 2021-2029 (USD Million)
107 Brazil RSV Vaccine Market, By Age Group, 2021-2029 (USD Million)
108 Brazil RSV Vaccine Market, By Route of Administration, 2021-2029 (USD Million)
109 Argentina RSV Vaccine Market, By Vaccine Type, 2021-2029 (USD Million)
110 Argentina RSV Vaccine Market, By Age Group, 2021-2029 (USD Million)
111 Argentina RSV Vaccine Market, By Route of Administration, 2021-2029 (USD Million)
112 Chile RSV Vaccine Market, By Vaccine Type, 2021-2029 (USD Million)
113 Chile RSV Vaccine Market, By Age Group, 2021-2029 (USD Million)
114 Chile RSV Vaccine Market, By Route of Administration, 2021-2029 (USD Million)
115 Rest of Central and South America RSV Vaccine Market, By Vaccine Type, 2021-2029 (USD Million)
116 Rest of Central and South America RSV Vaccine Market, By Age Group, 2021-2029 (USD Million)
117 Rest of Central and South America RSV Vaccine Market, By Route of Administration, 2021-2029 (USD Million)
118 GlaxoSmithKline plc (GSK): Products & Services Offering
119 Novavax, Inc.: Products & Services Offering
120 AstraZeneca plc: Products & Services Offering
121 Pfizer Inc.: Products & Services Offering
122 Sanofi Pasteur: Products & Services Offering
123 JOHNSON & JOHNSON - MERCK & CO., INC.: Products & Services Offering
124 Bavarian Nordic: Products & Services Offering
125 Bharat Biotec: Products & Services Offering
126 Serum Institute of India, Inc: Products & Services Offering
127 Other Companies: Products & Services Offering
LIST OF FIGURES
1 Global RSV Vaccine Market Overview
2 Global RSV Vaccine Market Value From 2021-2029 (USD Mllion)
3 Global RSV Vaccine Market Share, By Vaccine Type (2023)
4 Global RSV Vaccine Market Share, By Age Group (2023)
5 Global RSV Vaccine Market Share, By Route of Administration (2023)
6 Global RSV Vaccine Market, By Region (Asia Pacific Market)
7 Technological Trends In Global RSV Vaccine Market
8 Four Quadrant Competitor Positioning Matrix
9 Impact Of Macro & Micro Indicators On The Market
10 Impact Of Key Drivers On The Global RSV Vaccine Market
11 Impact Of Challenges On The Global RSV Vaccine Market
12 Porter’s Five Forces Analysis
13 Global RSV Vaccine Market: By Vaccine Type Scope Key Takeaways
14 Global RSV Vaccine Market, By Vaccine Type Segment: Revenue Growth Analysis
15 Viral Vaccine Market, By Region, 2021-2029 (USD Mllion)
16 Bacterial Vaccine Market, By Region, 2021-2029 (USD Mllion)
17 Global RSV Vaccine Market: By Age Group Scope Key Takeaways
18 Global RSV Vaccine Market, By Age Group Segment: Revenue Growth Analysis
19 Pediatric Market, By Region, 2021-2029 (USD Mllion)
20 Adult Market, By Region, 2021-2029 (USD Mllion)
21 Global RSV Vaccine Market: By Route of Administration Scope Key Takeaways
22 Global RSV Vaccine Market, By Route of Administration Segment: Revenue Growth Analysis
23 Intramuscular Market, By Region, 2021-2029 (USD Mllion)
24 Intranasal Market, By Region, 2021-2029 (USD Mllion)
25 Regional Segment: Revenue Growth Analysis
26 Global RSV Vaccine Market: Regional Analysis
27 North America RSV Vaccine Market Overview
28 North America RSV Vaccine Market, By Vaccine Type
29 North America RSV Vaccine Market, By Age Group
30 North America RSV Vaccine Market, By Route of Administration
31 North America RSV Vaccine Market, By Country
32 U.S. RSV Vaccine Market, By Vaccine Type
33 U.S. RSV Vaccine Market, By Age Group
34 U.S. RSV Vaccine Market, By Route of Administration
35 Canada RSV Vaccine Market, By Vaccine Type
36 Canada RSV Vaccine Market, By Age Group
37 Canada RSV Vaccine Market, By Route of Administration
38 Mexico RSV Vaccine Market, By Vaccine Type
39 Mexico RSV Vaccine Market, By Age Group
40 Mexico RSV Vaccine Market, By Route of Administration
41 Four Quadrant Positioning Matrix
42 Company Market Share Analysis
43 GlaxoSmithKline plc (GSK): Company Snapshot
44 GlaxoSmithKline plc (GSK): SWOT Analysis
45 GlaxoSmithKline plc (GSK): Geographic Presence
46 Novavax, Inc.: Company Snapshot
47 Novavax, Inc.: SWOT Analysis
48 Novavax, Inc.: Geographic Presence
49 AstraZeneca plc: Company Snapshot
50 AstraZeneca plc: SWOT Analysis
51 AstraZeneca plc: Geographic Presence
52 Pfizer Inc.: Company Snapshot
53 Pfizer Inc.: Swot Analysis
54 Pfizer Inc.: Geographic Presence
55 Sanofi Pasteur: Company Snapshot
56 Sanofi Pasteur: SWOT Analysis
57 Sanofi Pasteur: Geographic Presence
58 JOHNSON & JOHNSON - MERCK & CO., INC.: Company Snapshot
59 JOHNSON & JOHNSON - MERCK & CO., INC.: SWOT Analysis
60 JOHNSON & JOHNSON - MERCK & CO., INC.: Geographic Presence
61 Bavarian Nordic : Company Snapshot
62 Bavarian Nordic : SWOT Analysis
63 Bavarian Nordic : Geographic Presence
64 Bharat Biotec: Company Snapshot
65 Bharat Biotec: SWOT Analysis
66 Bharat Biotec: Geographic Presence
67 Serum Institute of India, Inc.: Company Snapshot
68 Serum Institute of India, Inc.: SWOT Analysis
69 Serum Institute of India, Inc.: Geographic Presence
70 Other Companies: Company Snapshot
71 Other Companies: SWOT Analysis
72 Other Companies: Geographic Presence
The Global RSV Vaccine Market has been studied from the year 2019 till 2029. However, the CAGR provided in the report is from the year 2024 to 2029. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process.
The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply-side analysis for the RSV Vaccine Market.
The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, distributors, and end-use product manufacturers.
Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: market attractiveness, current & future market trends, market share analysis, SWOT analysis of the company and customer analytics.
Frequently Asked Questions
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
Or view our licence options:
Tailor made solutions just for you
80% of our clients seek made-to-order reports. How do you want us to tailor yours?
OUR CLIENTS
